Interestingly, treatment with dinaciclib leads to the different distribution of cell cycle in our tested two ovarian cancer cells, which accompanies the distinct protein expressions of some important cell cycle related protein such as Cdk2 and cyclin E. Thus, the cell cycle responses of ovarian cancer cells to dinaciclib are variable and may be due to cellular genotype. Here, CDK2 is linked to ovarian cancer.